Syndax Pharmaceuticals (SNDX) Price & Analysis

Compare

741 Followers

SNDX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$8.58 - $22.50

Previous CloseN/A

Volume201.89K

Average Volume (3M)1.84M

Market Cap

$858.75M

Enterprise Value$892.05M

Total Cash (Recent Filing)$512.20M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.52

Next Earnings

Aug 04, 2025

EPS Estimate

-1.02

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding86,047,450

10 Day Avg. Volume1,843,434

30 Day Avg. Volume1,844,419

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap1.04

Enterprise Value/Revenue20.40

Enterprise Value/Gross Profit-593.91

Enterprise Value/Ebitda-2.74

Forecast

1Y Price Target

$31.67

Price Target Upside217.33% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering10

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe company is exploring broader use of its drug Revuforj in acute myeloid leukemia through combination studies, which could enhance its market potential.

Revenue OpportunityThe company is expected to have a significant revenue opportunity with its lead drug, Revuforj, which is approved for treating relapsed/refractory acute myeloid leukemia patients.

Bears Say

Adverse EventsManagement noted that physicians are experiencing a consistent adverse event profile versus clinical trials for Revuforj.

Uncertain OutlookNiktimvo’s longer-term outlook remains uncertain as use is expected to be reserved in transplant centers.

Syndax Pharmaceuticals News

Syndax price target lowered to $35 from $37 at UBS

UBS analyst David Dai lowered the firm’s price target on Syndax (SNDX) to $35 from $37 and keeps...

20d ago

SNDX

3 ‘Strong Buy’ Russell 2000 Stocks with Triple-Digit Upside Potential

As the market continues to navigate economic uncertainty, investors are increasingly looking toward smaller companies with high growth...

23d ago

AURA

NUVB

Syndax initiated with a Buy at Goldman Sachs

Goldman Sachs analyst Corinne Johnson initiated coverage of Syndax (SNDX) with a Buy rating and $18 price target...

25d ago

SNDX

SNDX Earnings this Week: How Will it Perform?

Syndax Pharmaceuticals Inc. (SNDX) is scheduled to report 2nd quarter earnings on 08/04/2025, after the market closes. Regarding...

2d ago

SNDX

Syndax Pharmaceuticals’ Promising AML Study: A Closer Look at SNDX-5613

Syndax Pharmaceuticals Inc. (($SNDX)) announced an update on their ongoing clinical study. Study Overview: Syndax Pharmaceuticals Inc. is...

11d ago

SNDX

Syndax Pharmaceuticals’ Axatilimab Study: A Potential Breakthrough for IPF Treatment

Syndax Pharmaceuticals Inc. (($SNDX)) announced an update on their ongoing clinical study. Syndax Pharmaceuticals Inc. is conducting a...

25d ago

SNDX

Promising Growth Potential for Syndax Pharmaceuticals Driven by Revuforj and Strategic Partnerships

Corinne Johnson, an analyst from Goldman Sachs, has initiated a new Buy rating on Syndax Pharmaceuticals (SNDX). Corinne...

25d ago

SNDX

William Meury Resigns from Syndax Pharmaceuticals Board

An update from Syndax Pharmaceuticals ( ($SNDX) ) is now available. On June 24, 2025, William Meury resigned...

1M ago

SNDX

Syndax granted priority review for Revuforj sNDA by FDA

Syndax (SNDX) announced that the FDA has granted priority review for its supplemental new drug application for Revuforj...

1M ago

SNDX

Promising Potential of Syndax Pharmaceuticals’ Revuforj Drives Buy Rating

Analyst Justin Zelin of BTIG reiterated a Buy rating on Syndax Pharmaceuticals (SNDX – Research Report), with a...

2M ago

SNDX

Syndax reports publication of revumenib data from BEAT AML trial

Syndax (SNDX) Pharmaceuticals announced that data from the BEAT AML trial of revumenib in combination with venetoclax and...

2M ago

SNDX

Syndax announces new data from AUGMENT-101 trial of Revuforj

Syndax (SNDX) Pharmaceuticals announced new data from the pivotal AUGMENT-101 trial of Revuforj, the Company’s first-in-class menin inhibitor,...

2M ago

SNDX

Syndax Pharmaceuticals: Promising 2025 Outlook and Strategic Product Launches Drive Buy Rating

Jefferies analyst Kelly Shi has maintained their bullish stance on SNDX stock, giving a Buy rating on May...

2M ago

SNDX

Closing Bell Movers: Trip.com slips 3% after results despite topping estimates

In the opening 30 minutes of the evening session, U.S. equity futures are mixed, with S&P 500 down...

3M ago

RHP

AGYS

SNDX FAQ

What was Syndax Pharmaceuticals Inc’s price range in the past 12 months?

Syndax Pharmaceuticals Inc lowest stock price was $8.58 and its highest was $22.50 in the past 12 months.

What is Syndax Pharmaceuticals Inc’s market cap?

Syndax Pharmaceuticals Inc’s market cap is $858.75M.

When is Syndax Pharmaceuticals Inc’s upcoming earnings report date?

Syndax Pharmaceuticals Inc’s upcoming earnings report date is Aug 04, 2025 which is today.

How were Syndax Pharmaceuticals Inc’s earnings last quarter?

Currently, no data Available

Is Syndax Pharmaceuticals Inc overvalued?

According to Wall Street analysts Syndax Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Syndax Pharmaceuticals Inc pay dividends?

Syndax Pharmaceuticals Inc does not currently pay dividends.

What is Syndax Pharmaceuticals Inc’s EPS estimate?

Syndax Pharmaceuticals Inc’s EPS estimate is -1.02.

How many shares outstanding does Syndax Pharmaceuticals Inc have?

Syndax Pharmaceuticals Inc has 86,047,450 shares outstanding.

What happened to Syndax Pharmaceuticals Inc’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Syndax Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in SNDX

Syndax Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-93.70%

Trailing 12-Months

Asset Growth

17.99%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Syndax Pharmaceuticals Inc

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML); and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD). The company is also developing Entinostat. It also has collaborative research and development agreement with National Cancer Institute; a clinical trial agreement with Eastern Cooperative Oncology Group; and a license agreement with Kyowa Hakko Kirin Co., Ltd. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.Massachusetts.

Syndax Pharmaceuticals (SNDX) Earnings & Revenues

SNDX Earnings Data >

SNDX Company Deck

SNDX Earnings Call

Q1 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive sentiment with strong initial sales of newly launched products and promising developments in the pipeline. While there are some uncertainties regarding market size and reimbursement, the overall outlook is optimistic due to financial stability and strategic advancements.Read More>

SNDX Stock 12 Month Forecast

Average Price Target

$31.67

▲(217.33%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"7":"$7","46":"$46","16.75":"$16.75","26.5":"$26.5","36.25":"$36.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$31.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[7,16.75,26.5,36.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.82,11.603076923076923,14.386153846153846,17.169230769230772,19.95230769230769,22.735384615384618,25.51846153846154,28.301538461538463,31.084615384615386,33.86769230769231,36.65076923076923,39.433846153846154,42.21692307692308,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.82,10.577692307692308,12.335384615384616,14.093076923076925,15.850769230769231,17.60846153846154,19.36615384615385,21.123846153846156,22.88153846153846,24.63923076923077,26.39692307692308,28.154615384615386,29.912307692307696,{"y":31.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.82,9.44923076923077,10.07846153846154,10.707692307692309,11.336923076923078,11.966153846153848,12.595384615384615,13.224615384615385,13.853846153846154,14.483076923076924,15.112307692307693,15.741538461538461,16.37076923076923,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":21.53,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.89,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.98,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.7,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.22,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.17,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.64,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.01,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.82,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.98,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.82,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >